Deregulated expression of ETS transcription factors has emerged as an important event in prostate cancer pathogenesis. Here we show that the expression of epithelial-specific ETS (ESE)-3 factor is frequently reduced at the RNA and protein level in prostate cancer clinical samples compared to normal prostate. In PC3 and DU145 cells, ESE-3 was silenced by methylation of an evolutionarily conserved CpG site in its promoter and treatment with 5-aza-2 0 -deoxycytidine restored its expression. In a prostate epithelial cell transformation model, methylation of this site was inversely correlated with ESE-3 expression and occurred only in Ras-transformed and tumorigenic cells and not in normal and immortalized cells suggesting that ESE-3 silencing was functionally linked to oncogenic transformation. Consistent with a tumor suppressor function, re-expression of ESE-3 in prostate cancer cells inhibited clonogenic survival and induced apoptotic cell death. ESE-3 increased the level of procaspase-3, a key element in the apoptotic cascade. This effect was mediated at the transcriptional level by direct binding of ESE-3 to the caspase-3 promoter. Collectively, our findings implicate ESE-3 as a candidate tumor suppressor in prostate cancer. Decreased expression of ESE-3 may result in loss of important regulatory mechanisms in prostate epithelial cells and contribute to the pathogenesis of prostate cancer.
Introduction
Prostate cancer (PCa) is the most common cancer and the second leading cause of cancer death in men in Western countries (Nelson et al., 2003) . The molecular pathology of PCa is highly complex suggesting that multiple oncogenes and tumor suppressor genes contribute to its pathogenesis (Nelson et al., 2003) . Recently, ETS transcription factors have emerged as important elements in the pathogenesis of PCa. The ETS gene family is one of the largest family of transcriptional regulators and includes 30 distinct members (Oikawa and Yamada, 2003; Seth and Watson, 2005) . ETS factors share a highly conserved DNA-binding domain and bind to conserved ETSbinding sites in the promoter of target genes (Oikawa and Yamada, 2003; Seth and Watson, 2005) . Individual ETS factors have distinct properties and can function both as transcriptional activators and repressors (Oikawa and Yamada, 2003; Seth and Watson, 2005) . Translocations, amplification and overexpression of ETS genes are found in leukemia, lymphomas and solid tumors (Seth and Watson, 2005) . The oncogenic activity of ETS factors is attributed to their ability to induce expression of genes that promote cell proliferation and survival (Seth and Watson, 2005) . However, not all ETS factors have transforming activity and some, like PU.1, TEL, MEF/ELF4 and PE1/METS, can have tumor suppressor properties (Seth and Watson, 2005) . Increased expression of ETS genes, like ETS-2 and ERG with oncogenic activity, has been reported in PCa (Liu et al., 1997; Petrovics et al., 2005) . Recently, ERG and other ETS have been found to be frequently fused to the androgen-regulated TMPRSS2 gene in PCa (Tomlins et al., 2005 (Tomlins et al., , 2006 . TMPRSS2 is a prostate-specific serine protease and transcription of the fusion genes is driven by an androgen responsive element in the TMPRSS2 gene promoter leading to elevated expression in PCa cells (Tomlins et al., 2005 (Tomlins et al., , 2006 .
ETS genes constitute a complex network of transcriptional regulators (Oikawa and Yamada, 2003; Seth and Watson, 2005) . In many cells, multiple ETS factors with similar or opposite functions are present simultaneously and the cell's fate may depend ultimately on the balance between the activity of distinct ETS factors (Oikawa and Yamada, 2003; Seth and Watson, 2005) . The subgroup of epithelial-specific ETS (ESE) factors, including ESE-1, ESE-2 and ESE-3, is expressed primarily in cells of epithelial origin and may have a critical function in epithelial cell differentiation and proliferation (Oikawa and Yamada, 2003; Seth and Watson, 2005) . Thus, altered expression of ESE factors might affect the normal process of epithelial cell differentiation and contribute to cell transformation (Kas et al., 2000; Tugores et al., 2001; Schedin et al., 2004; Tummala and Sinha, 2006) .
In this study, we examined ESE-3 expression in tumor and normal prostatic tissues. ESE-3 was significantly downregulated in PCa both at the mRNA and protein level. ESE-3 was silenced by methylation in PCa cell lines, like DU145 and PC3. ESE-3 was expressed in normal and immortalized prostate epithelial cells (PrEC) but not in transformed cells, suggesting that its silencing was functionally linked to oncogenic transformation. ESE-3 directly controlled transcription of the caspase-3 gene, the key downstream executioner caspase in the apoptotic cascade. Re-expression of QJ;ESE-3 in PCa cells inhibited clonogenic survival, increased procaspase-3 level and induced apoptosis. Thus, ESE-3 behaves like a tumor suppressor in PrECs and silencing of ESE-3 may contribute to the pathogenesis of PCa.
Results

ESE-3 expression is reduced in PCa
We examined microarray data sets from PCa clinical samples and normal prostate to derive information on the expression of ESE-3. PCa samples were taken from patients who underwent radical prostatectomy, while normal prostate tissue was taken from adult male who underwent multiple diagnostic prostate biopsies and found to be disease free. The level of ESE-3 was significantly lower in PCa than in normal prostate ( Figure 1a) . On the contrary, AMACR, a marker expressed in neoplastic glandular epithelium, was elevated in tumors compared to normal prostate ( Figure 1b) . Microarray data indicated that other ETS genes, like ERG and less frequently ETV1 and ETV4, were upregulated as reported previously (Petrovics et al., 2005; Tomlins et al., 2005 Tomlins et al., , 2006 . Thus, ESE-3 might have a distinct behavior and function in PCa compared to other ETS factors.
Validation of the microarray data was carried out using quantitative reverse transcriptase (qRT)-PCR and immunohistochemistry. As shown in Figure 1c , qRT-PCR in each patient, confirmed that ESE-3 expression was significantly lower in PCa compared to normal prostate (Po0.001). ESE-3 RNA was reduced X2-fold in 80% and X4-fold in 50% of PCa samples (Figure 1d ). Reduced expression of ESE-3 in PCa was also assessed by immunohistochemistry. Intense nuclear staining was seen in PrECs in normal tissue while it was absent or greatly reduced in PCa samples (Figure 1e ). Stromal cells were negative for ESE-3 both in normal and tumor samples. Taken together, these data supported the hypothesis that reduced expression of ESE-3 might be an early and common event in PrEC transformation.
ESE-3 expression in PCa cells
Expression of ESE-3 was examined in PCa cell lines by RT-PCR and immunoblotting. ESE-3 RNA was very low or undetectable in PC3 and DU145 cells, while relatively higher levels were present in LNCaP and 22Rv1 cells (Figure 2a) . Two splice variants, ESE-3a and ESE-3b, have been described, the second one having a 69-bp insert in the central portion (Kas et al., 2000) . ESE-3b was the predominant transcript both in LNCaP cells and tissue specimens (Figure 2b) . Consistent with the RT-PCR data, immunoblotting showed that LNCaP and 22RV1 cells expressed ESE-3, while DU145 and PC3 did not (Figure 2c, left panel) . In LNCaP cells ESE-3 localized predominantly to the cell nucleus as seen in normal PrECs (Figure 2c , right panel).
ESE-3 expression was examined also in normal and primary PrECs that had been immortalized (LH and LHS) or transformed (LHR and LHSR) by expression of either hTERT, SV40 large and small T antigen, or oncogenic H-Ras (Berger et al., 2004) . While LH and LHS cells are non-tumorigenic, LHR and LHSR cells are partially or fully transformed and tumorigenic (Berger et al., 2004) . ESE-3 RNA was present in normal (PrEC) and immortalized cells (LH and LHS), but not in Ras-transformed cells (LHR and LHSR) (Figure 2d , left panel). Immunoblotting confirmed that ESE-3 was differentially expressed among normal, immortalized and transformed PrEC (Figure 2d , right panel). Thus, ESE-3 downregulation was associated with the acquisition of a transformed phenotype in this PrEC model.
Epigenetic silencing of ESE-3 in PCa cells
We considered whether reduced expression of ESE-3 was due to DNA methylation and examined the effects of the demethylating agent 5-AdC in PCa cells that had low or undetectable ESE-3 levels. Following treatment with 5-AdC, ESE-3 expression increased in both PC3 and DU145 cells, suggesting that the gene was subject to methylation-mediated silencing (Figure 3a) . The ESE-3 gene did not contain CpG islands. Isolated CpG dinucleotides were present within a short distance of the gene's transcriptional start site. Two of these isolated sites, at À45 and À692 with respect to the transcriptional start site, overlapped sequences recognized by the methylation sensitive restriction enzymes HpaII and MspI. Interestingly, conservation analysis indicated that the À45 CpG site was highly conserved among several species and overlapped putative transcription factor binding sites (that is, AP2 and nuclear factor-kB) (Supplementary Figure S1) . To determine the methylation state of these CpG sites, genomic DNA from PCa cells was incubated with HpaII and MspI and was subjected to PCR using primer sets flanking the sites. The À45 CpG site was not cut by HpaII in PC3 and DU145 cells, indicating that it was methylated (Figure 3b ). In contrast, the À45 site was unmethylated in 22Rv1 and LNCaP cells (Figure 3b ). The methylation state of the À45 CpG site in LNCaP and DU145 cells was confirmed by sequencing of bisulfite-treated DNA ESE-3 transcription factor in prostate cancer R Cangemi et al ( Figure 3c ). The À692 CpG site was also differentially methylated among the four PCa cell lines (Figure 3b ). Overall, methylation of CpG sites in the ESE-3 promoter region, particularly the À45 site, correlated well with the level of expression of ESE-3 in PCa cell lines.
Transcriptional silencing and CpG methylation at the À45 site were also tightly coupled in the in vitro PrEC transformation model (Figure 3d ). The À45 CpG site was not methylated in normal and immortalized PrEC that expressed ESE-3, while it was methylated in the Ras-transformed and tumorigenic PrEC. Taken (e) ESE-3 protein expression in normal prostate (top) and prostate cancer (bottom) tissue specimens. Tissue sections were prepared from paraffin-embedded specimens and stained using an anti-ESE-3 rat monoclonal antibody. Representative images of normal and tumor samples are shown at lower ( Â 40) and higher ( Â 80) magnification in left and right panels, respectively. Intense nuclear staining of prostate epithelial cells is seen in normal prostate and absent in tumor specimens. ESE, epithelial-specific ETS; PCa, prostate cancer; RT, reverse transcriptase.
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Re-expression of ESE-3 in PCa cells inhibits clonogenic survival
The pattern of expression in clinical samples and the evidence of epigenetic silencing suggested that ESE-3 might behave as a tumor suppressor in PrEC. To provide evidence in support of this hypothesis, PCa cells with low or intermediate expression of ESE-3 were transfected with an ESE-3 expression vector or empty vector. Immunoblots showed high ESE-3 expression in transfected cells (Figure 4a ), confirmed also by FACS (data not shown). Furthermore, ESE-3 had a predominantly nuclear localization in transfected cells as shown both by immunoblotting ( Figure 4b ) and fluorescence microscopy (data not shown), consistent with the subcellular localization of endogenous ESE-3 in PrECs.
To examine the functional consequences of ESE-3 expression, clonogenic assays were performed under selective conditions with ESE-3 and control transfected cells. The number of colonies formed by ESE-3 transfected cells was reduced significantly compared to cells transfected with control vector, indicating that ESE-3 affected negatively clonogenic survival of PCa cells ( Figure 4c ). We also attempted to establish stable clones of ESE-3-expressing PCa cells, but were unable to do so. The inability to isolate stable ESE-3-expressing clones provided additional support to the hypothesis that ESE-3 was a negative regulator of growth and survival of PCa cells.
ESE-3 promotes apoptosis of PCa cells
To investigate the mechanisms by which ESE-3 affected clonogenic survival, we assessed caspase-3 activation and PARP cleavage, two well established and sensitive markers of apoptosis, after re-expression of ESE-3 in PCa cells. Both active caspase-3 and cleaved PARP (85 kDa cleaved fragment) were detected in ESE-3-expressing cells at 48 and 72 h after transfection, while they were absent in control transfected cells (Figure 5a ). Interestingly, higher levels of procaspase-3 were found in ESE-3-expressing cells compared to control cells, indicating that ESE-3 also increased the amount of the proenzyme in addition to the active form (Figure 5b ). The amount of procaspase-3 was proportional to the level of the ESE-3 achieved upon transfection of increasing amounts of expression vector (data not shown). The increase of both procaspase-3 and active caspase-3 was blocked by co-transfection of an ESE-3 small interfering RNA along with ESE-3 expression vector, confirming that the effects were due to the expression of ESE-3 and were not a nonspecific consequence of the transfection (Figure 5c ). Control small interfering RNA (siGL3) and vector (pcDNA) did not have any effect on procaspase-3 and active caspase-3. A similar increase of procaspase-3 was seen in DU145 and 22Rv1 cells upon re-expression of ESE-3 (data not shown). The ability of ESE-3 to induce caspase-3 and promote apoptotic cell death is consistent with a tumor suppressor role of this transcription factor.
ESE-3 controls caspase-3 expression ETS transcription factors control many genes involved in the apoptotic cascade (Sementchenko and Watson, 2000) . We observed increased procaspase-3 levels in ESE-3 transfected cells and hypothesized that ESE-3 could control transcription of the caspase-3 gene. In support of our hypothesis, the level of caspase-3 RNA was strikingly parallel to that of ESE-3 in PCa cell lines. LNCaP and 22Rv1 cells had high and intermediate 
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R Cangemi et al levels of caspase-3, while lower levels were present in DU145 and PC3 cells (Figure 6a ). To determine whether ESE-3 could induce caspase-3 transcription, we performed reporter assays using a rat caspase-3 promoter construct (Liu et al., 2002) . The rat promoter contains ETS-binding sites and similar sites were found in the human caspase-3 promoter by computer-based searches of transcription factor binding sites. Caspase-3 ESE-3 transcription factor in prostate cancer R Cangemi et al promoter activity increased B3-fold when cells were transfected with ESE-3 expression vector compared to control vector (Figure 6b ). Next, we determined whether transcription of the endogenous caspase-3 gene was induced upon re-expression of ESE-3 in PC3 cells. Caspase-3 RNA was consistently higher in ESE-3 transfected PC3 cells compared to control cells (Figure 6c ). These data were consistent with the hypothesis that ESE-3 controlled transcription of this key apoptotic factor. To provide direct evidence of binding of ESE-3 to caspase-3 promoter, we performed chromatin immunoprecipitation upon transfection of PC3 cells with the ESE-3 expression or control vector. Binding of ESE-3 to a region (À318 to À467 bp) of the caspase-3 promoter containing a putative ETS-binding site was detected in ESE-3-expressing cells, but not in control transfected cells (Figure 6d) . No binding was detected to a more distal region (À784 to À924 bp) containing an additional putative ETS-binding site (data not shown).
Discussion
ETS transcription factors constitute a complex regulatory network that controls cell homeostasis in a variety of tissues (Oikawa and Yamada, 2003; Seth and Watson, 2005) . In many cells, multiple ETS genes are simultaneously expressed and the balance between ETS factors with distinct activities may decide whether cells undergo proliferation, differentiation or death (Oikawa and Yamada, 2003; Seth and Watson, 2005) . ETS genes with oncogenic potential are frequently overexpressed in PCa (Liu et al., 1997; Petrovics et al., 2005) . Chromosomal translocations involving ETS genes are present in about 50% of PCa, representing altogether one of the most frequent genetic events in this disease (Tomlins et al., 2005 (Tomlins et al., , 2006 . On the other hand, a subset of ETS factors, including ESE-3, is preferentially expressed in differentiated epithelial cells of glandular organs, like prostate and breast, and may have a critical role in controlling epithelial cell fate (Kas et al., 2000; Tugores et al., 2001) . In this study, we show that ESE-3 functions as a tumor suppressor in the prostate, negatively affecting growth and survival of PCa cells. Our data suggest that loss of ESE-3 expression is an important PC3 cells transfected with control (À) or ESE-3 expression ( þ ) vector were analysed by western blots with antibodies specific for ESE-3, active caspase-3, cleaved PARP (85 kDa cleaved fragment) and a-tubulin. (b) Induction of procaspase-3 by ESE-3. Cells were harvested at the indicated time after transfection and analysed by western blot using antibodies specific for ESE-3, procaspase-3 and a-tubulin. (c) ESE-3 siRNA abolishes the effects of ESE-3 on caspase-3. PC3 cells were transfected with ESE-3 or control vector along with ESE-3 (siESE-3) or control (siGL3) siRNA, harvested after 48 h and analysed by western blot with the indicated antibodies. ESE, epithelial-specific ETS; PARP, poly (ADP-ribose) polymerase siRNA, small interfering RNA. promoter. PC3 cells were transfected with ESE-3 or control vector and chromatin immunoprecipitation was performed using antibodies against ESE-3 or RNA polymerase II. PCR was performed with primers spanning the À318 to À467 region of the caspase-3 promoter. Lanes 1 and 5, ESE-3 transfected cells, pull down with anti-ESE-3 antibody; lanes 2 and 6, ESE-3 transfected cells, pull down without antibody; lanes 3 and 7, ESE-3 transfected cells, pull down with anti-RNA polymerase II antibody; lanes 4 and 8, cells transfected with control vector, pull down with anti-ESE-3 antibody. ESE, epithelialspecific ETS; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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R Cangemi et al event in the pathogenesis of PCa in addition to the activation of oncogenic ETS factors. These data provide novel insights into the complex functions of the ETS transcriptional network in prostate tumorigenesis. To our knowledge this is the first study to examine ESE-3 expression in a large number of normal and tumor specimens. We found that about half of PCa had an almost complete loss of ESE-3 expression (X80% reduction) and about 80% of PCa had X2-fold reduction compared to the average level in normal prostate. Thus, the frequency of ESE-3 downregulation is comparable or superior to other gene alterations found in PCa, including ETS gene overexpression. Indeed, given its high frequency, downregulation of ESE-3 is likely to occur in tumors in which other ETS genes are overexpressed. The hypothesis that ESE-3 downregulation might contribute to transformation of PrEC is particularly intriguing. Reduced ESE-3 level by epigenetic or genetic events may enhance the oncogenic activity of other ETS factors.
The restricted pattern of ESE-3 expression suggests that this transcription factor is involved in epithelial cellspecific processes. ESE-3 was shown to activate the promoters of genes associated with a differentiated phenotype in reporter assays (Kas et al., 2000) . ESE-3 acted also as a repressor of a subset of Ras-responsive genes involved in mitogenesis, cell migration and cell interactions (Tugores et al., 2001) . Thus, ESE-3 could regulate the equilibrium between proliferation and differentiation through both activation and repression of selected target genes and control the induction and maintenance of PrEC differentiation. In this regard, the role of ESE-3 in epithelial cells might be similar to that of PU.1 in hematopoietic cells. PU.1 is essential for normal hematopoiesis, and its activation commits hematopoietic progenitor cells to either the myeloid or lymphoid lineages (Laslo et al., 2006) . Hematopoietic progenitor cells with reduced levels of PU.1 fail to differentiate, acquire self-renewal capacity and are prone to transformation leading to acute myeloid leukemia (Rosenbauer et al., 2004) . Loss of ESE-3 expression may similarly impair the ability of PrEC to differentiate and promote cell transformation.
Our data suggest that DNA methylation could be a cause of reduced expression of ESE-3 in PCa. Epigenetic silencing is highly relevant in cancer pathogenesis (Baylin and Ohm, 2006) . Early epigenetic alterations in key genes can promote clonal expansion of premalignant cells and predispose to further accumulation of genetic and epigenetic changes that drive tumor progression (Baylin and Ohm, 2006) . Isolated CpG dinucleotides were located within a short distance of the ESE-3 transcriptional start site. The proximal À45 CpG site was adjacent to putative transcription factor binding sites (that is, AP2 and nuclear factor-kB) that could be important for regulating ESE-3 expression. Methylation of the À45 site was inversely correlated with the level of ESE-3 expression in PCa cell lines and primary PrEC. The site was methylated in the Ras-transformed and tumorigenic PrECs, but not in normal and immortalized PrECs, suggesting that ESE-3 silencing was functionally linked to oncogenic transformation of PrECs. Methylation of single promoter sites has been reported to mediate transcriptional repression of several genes, including the p53 tumor suppressor gene (Pogribny et al., 2000; Kang et al., 2001) . Methylation of an isolated CpG site in the p16 promoter was sufficient to reduce promoter activity by 50% (Gonzalgo et al., 1998) , whereas demethylation of a single CpG site in the EBV latency C promoter by 5-AdC activated transcription (Robertson et al., 1995) . Thus, methylation of isolated CpG sites, like those found in the ESE-3 promoter, can mediate transcriptional repression, perhaps by blocking binding of transcriptional activators or promoting binding of transcriptional repressors (Jones and Chen, 2006) .
To understand the function of ESE-3 in cell transformation and the underlying mechanisms, we evaluated the consequences of its re-expression in PCa cells. Reexpression of ESE-3 inhibited clonogenic growth and was associated with the induction of apoptotic cell death. Thus, in addition to control PrEC differentiation, ESE-3 might play a protective role promoting cell death and preventing clonal expansion of premalignant cells. This protective function might be essential under conditions, like chronic inflammation and oxidative stress, and might depend on the ability of ESE-3 to control caspase-3 expression. Caspase-3 is a key regulator of apoptosis and is the major downstream caspase, central to both the extrinsic and intrinsic pathways (Igney and Krammer, 2002) . Computer-based searches identified putative ETS-binding sites in the human caspase-3 promoter and chromatin immunoprecipitation confirmed binding of ESE-3 to the most proximal site, indicating that the gene is a direct transcriptional target of ESE-3. Other ETS factors have been shown to control transcription of apoptosisassociated genes (Sementchenko and Watson, 2000) . The p42 variant of ETS-1 was shown to bind to the caspase-1 promoter and activate its transcription (Pei et al., 2005) . Increased production of caspase-1 was important for induction of apoptosis by p42 ETS-1 in colon cancer cells (Pei et al., 2005) .
Considering the key role of caspase-3 in the execution of the apoptotic program, silencing of ESE-3 with consequent reduction of caspase-3 expression might also be responsible for decreased sensitivity of PCa cells to apoptotic stimuli. This may have direct implications for clinical management of PCa, since the level of ESE-3 might be predictive of response to apoptosis-inducing therapies. On the other hand, approaches aimed at restoring ESE-3 expression or function might be an effective therapeutic strategy to increase sensitivity of PCa to treatment.
Materials and methods
Cell lines, plasmids, cell culture conditions Androgen receptor negative DU145 and PC3 cells and androgen receptor positive LNCaP and 22Rv1 cells were obtained from American Type Culture Collection and maintained in RPMI-1640 (GIBCO, Invitrogen AG, Basel, Switzerland) supplemented with 10% fetal bovine serum. Normal ESE-3 transcription factor in prostate cancer R Cangemi et al PrECs (Cambrex, Lonza Group Ltd, Basel, Switzerland) and the immortalized and transformed LH, LHS, LHR, LHSR cell derivatives (Berger et al., 2004) were maintained in PrEC growth medium (PrEGM) with growth supplements (Cambrex) . LH cells express hTERT and SV40 large T antigen; LHS cells express hTERT, SV40 large T and small t antigen; LHR express hTERT, SV40 large T and H-ras; LHSR express hTERT, SV40 large T and small t antigen, and H-ras (Berger et al., 2004) . The pRc/CMV-ESE3b-FLAG, pSGK-ETS2 and pGL3-CASP3 have been described previously (Tugores et al., 2001; Liu et al., 2002; Carbone et al., 2004) . Transfections were performed using Lipofectamine 2000 (Invitrogen AG, Basel, Switzerland) according to the manufacturer's instructions. Treatment with 5-aza-2 0 -deoxycytidine (5-AdC, 5-25 mM; Sigma) was started 24 h after seeding and continued for 48 or 96 h.
Tissue collection
Tissue samples were collected according to a protocol approved by the Institutional Ethics Committees and after patient's informed consent. PCa samples (n ¼ 60) were taken from patients who underwent radical prostatectomy and immediately frozen in liquid nitrogen. All samples were evaluated by a pathologist and trimmed to ensure that they were representative of the desired lesion. Tumor stage was pT2 in 67% and XT3 in 33% of cases. Gleason score was p6 in 20%, 7 in 58% and X8 in 22% of cases. Normal prostate tissue (n ¼ 8) was taken from adult male who underwent multiple diagnostic prostate biopsies and found to be diseasefree. The age range of individuals with cancer and normal prostate was 50-74 and 48-78 years, respectively.
Microarray
Total RNA extracted from tissue specimens was amplified and labeled using Ambion Message Amp I. Cy3-and Cy5-labeled RNAs were hybridized with a dye-swap replication scheme on Human 1A glass arrays (Agilent Technologies, Santa Clara, CA, USA). Arrays were scanned with the Agilent B scanner and raw data files were loaded into the Resolver SE System (Rosetta Biosoftware, Seattle, WA, USA) for data normalization and processing applying the Agilent platform-specific error model. A commercial pool of RNA from organ donor healthy prostates (Becton Dickinson (BD), NJ, USA) was used as common reference and allowed to calculate expression ratios in normal and tumor samples relative to the average expression in normal prostate samples.
RT-PCR
Quantitative real-time RT-PCR (qRT-PCR) was performed using the ABI 7000 sequence detection system and SYBR Green chemistry. Primer sequences are available as supplemental material (Supplementary Table S1 ). Total RNA (1 mg) was reverse-transcribed using the two-step RT-PCR system (Invitrogen). The resulting cDNA was used as template in qRT-PCR. Primers for ESE-3 were designed to amplify a region in the 3 0 -untranslated region corresponding to the location of the microarray probe. b-Actin was used as control of the input RNA level. Titration experiments were performed to determine optimal concentrations of ESE-3 and b-actin primers. Standard curves for ESE-3 and b-actin were constructed using serially diluted cDNA from LNCaP cells. Verification of specific product amplification was determined by dissociation curve analysis. Conventional RT-PCR was performed using SuperScript One-step RT-PCR System (Invitrogen) and primer sets indicated in Supplementary Table  S1 . PCR products were analysed by gel electrophoresis and visualized using the AlphaImager 3400 (AlphaInnotech Corporation, Fremont, CA, USA).
Immunohistochemistry
Tissue sections were prepared from paraffin-embedded human prostate tissues. Sections were de-waxed in xylol, rehydrated in ethanol and treated with antigen retrieval solution (DAKO Schweiz AG Baar, Switzerland) as recommended by the manufacturer. Immunohistochemistry was carried out using anti-ESE-3 rat monoclonal antibody (1:20 dilution, LabVision Corporation, San Leandro, CA, USA) followed by incubation with a secondary mouse anti-Rat Ab (DAKO).
DNA methylation
Genomic DNA was incubated with HpaII and MspI for 3 h. PCR amplification was performed using primers flanking the À45 and À692 CpG sites and AmpliTAq Gold (Applied Biosystems, Rotkreuz, Switzerland). PCR amplification of ESE-3 exon 7 was used as control. PCR products were resolved on 2% agarose gels. For sequencing, genomic DNA was treated using the Epitect Bisulphite kit (Qiagen AG Hombrechtikon, Switzerland) according to the manufacturer's protocol. Bisulfite-modified DNA was then amplified and sequenced.
Immunoblotting Cell lysates were prepared as described previously (Catapano et al., 2000; Carbone et al., 2004) . Cytoplasmic and nuclear fractions were isolated as described (Catapano et al., 2000) . Proteins from tissue specimens extracted in Tri-reagent (Sigma) were recovered according to the manufacturer's protocol. Proteins were resolved on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and analysed by western blot using enhanced chemiluminescence system (Amersham-Pharmacia, GE Healthcare, Otelfingen, Switzerland). Antibodies against ESE-3 (A Tugores, Hospital Las Palmas, Spain), ETS2 (Santa Cruz Biotechnology Inc., Heidelberg, Germany), procaspase-3 (Cell Signaling Technology Inc., Danvers, MA, USA), active caspase-3 (Epitomics Burlingame, CA, USA), 85 kDa cleaved fragment of PARP-1 (clone F21-852BD, BD Bios Pharmingen, Basel, Switzerland), a-tubulin (Calbiochem, Nottingham, UK) were obtained from the indicated sources.
Colony forming assays Cells were transfected with pRc/CMV-ESE3b-FLAG or control vector, allowed to grow for 24 h and then plated (5 Â 10 3 to 10 Â 10 3 cells per well). Neomycin-resistant cells were selected in presence of G418 (400 mg ml À1 ). After 10-12 days, cells were fixed and stained with 1% crystal violet in 20% ethanol and counted. Each experiment was carried out in triplicate and repeated at least three times.
RNA interference
Small interfering RNAs targeting a sequence in exon 3 of ESE-3 (ESE-3 small interfering RNA) and the luciferase gene (siGL3) were purchased from Ambion (Ambion, Austin, TX, USA). PC3 cells were plated in six-well plates and after 24 h transfected with 100 nM ESE-3 small interfering RNA or siGL3 along with ESE-3 expression or control vector. Cells were harvested after 48 h for protein extraction and western blotting.
Luciferase reporter assays Cells were plated in 24-well plates and transfected with pGL3-CASP3 along with the ESE-3 expression or control vector. pRL-SV40 (Promega AG, Wallisellen, Switzerland) was used as control vector to monitor transfection efficiency. Luciferase activity was measured after 24 h using the Dual-Luciferase ESE-3 transcription factor in prostate cancer R Cangemi et al
Reporter Assay System (Promega) as described by the manufacturer. Reporter assays were performed in triplicate and repeated in three independent experiments.
Chromatin immunoprecipitation PC3 cells were transfected with ESE-3 expression or control vector, allowed to grow for 24 h and then exposed to formaldehyde to crosslink protein-DNA complexes. Cells were processed using the chromatin immunoprecipitation kit from Upstate Biotechnology according to the manufacturer's recommended protocol. Chromatin was immunoprecipitated with an anti-ESE-3 antibody or anti-RNA polymerase II (Upstate Biotechnology, NY, USA) as control. PCR was performed using primer sets spanning two regions (À318 to À467 and À784 to À924) comprising the ETS-binding sites identified in the human caspase-3 promoter by computer searches. Primer sequences are shown in Supplementary Table  S1 . PCR products were analysed by gel electrophoresis.
Statistics
Statistical significance of differential findings between experimental groups was assessed by Student's t-test.
